SAMPLE — NOT LEGAL ADVICE. This response letter was generated automatically from publicly available analysis. It has NOT been reviewed by a licensed attorney and SHOULD NOT BE SENT to any party without substantial review and customization by qualified patent counsel. Use as a starting point only.

[Your Name]
[Your Title]
[Your Company]
[Street Address, City, State ZIP]

May 14, 2026

[Opposing Counsel Name]
[Firm Name]
[Address]

Re: U.S. Patent No. 12377204 — Response to Assertion of Infringement

Dear Counsel,

We acknowledge receipt of your correspondence asserting infringement of U.S. Patent No. 12377204 (the "12377204 Patent"). After preliminary review, we have substantial concerns about the validity, enforceability, and scope of the asserted claims, summarized below. We reserve all rights and defenses.

1. Subject Patent — Summary

A concise summary of US Patent 12377204 is as follows:
Title: System and method for collecting plasma
Assignee: Haemonetics Corp
Inventor: Michael Ragusa
Filing Date: March 12, 2025
Issue Date: August 5, 2025
Abstract:
A method for collecting plasma includes determining the weight, height, and hematocrit of a donor, and calculating a donor plasma volume and a target plasma collection volume. The target plasma collection volume is based on the donor plasma volume and a target percentage of plasma. The method then withdraws blood from the donor through a line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component…

2. Validity Concerns under 35 U.S.C. § 102 — Prior Art

We have identified prior-art references that, in our preliminary view, anticipate one or more asserted claims of the 12377204 Patent:

Based on the information available for US patent 12,377,204 and its family, a review of the most relevant prior art has been conducted. The provided text for patent 12,377,204 does not itself contain a "References Cited" section. Therefore, this analysis identifies the most relevant prior art by examining the prosecution history of its direct parent and grandparent patents in the same family, as these references were likely considered during the examination of the '204 patent itself.

The following prior art references are considered highly relevant to the claims of US patent 12,377,204.

Analysis of Key Prior Art

1. US Patent 5,728,058 A (Re-issued as RE39,486 E1)

• Full Citation: US Patent 5,728,058 A, "Method and apparatus for controlling the volume of collected plasma", Re-issued as RE39,486 E1.

• Assignee: Baxter International Inc.

• Filing Date: June 7, 1995

• Issue Date: March 17, 1998

• Brief Description: This patent describes a plasmapheresis system that estimates the volume of plasma collected from a donor. It calculates the amount of plasma in the collection container…

3. Obviousness under 35 U.S.C. § 103

Independent of § 102, we believe the asserted claims are obvious in view of combinations of prior art that a person having ordinary skill in the art would have been motivated to combine:

Based on the provided patent documentation and prior art analysis, here is an assessment of the obviousness of US patent 12,377,204 under 35 U.S.C. § 103 as of April 26, 2026.

Definition of a Person Having Ordinary Skill in the Art (PHOSITA)

A person having ordinary skill in the art (PHOSITA) for this invention would be a biomedical engineer or a related professional with several years of experience in designing and developing blood apheresis systems. This individual would be knowledgeable about the principles of extracorporeal blood circulation, centrifugation, FDA regulations for plasma donation, and the physiological variables of donors, such as hematocrit and total blood volume.

Core Inventive Concepts of US Patent 12,377,204

The claims of the '204 patent are directed toward a system and method for plasma collection that combines two key features:

1. Personalized Collection Target: Calculating a donor-specific target collection volume based on the donor's height, weight, and hematocrit to determine their total plasma volume, and then targeting a specific percentage of that…

4. Litigation History of the Patent

Public records reflect that the 12377204 Patent has been the subject of the following litigation, which informs our view of the asserted claims and your client's enforcement posture:

• Haemonetics Corporation v. Terumo BCT, Inc. — 1:25-cv-01409 · United States District Court for the District of Colorado · filed 2025-05-05 · Ongoing

• Haemonetics Corp. v. Terumo BCT, Inc. — 1:25-cv-01409-RMR-SBP · U.S. District Court for the District of Colorado · filed 2025-05-05 · active

5. Request

In light of the foregoing, we request that your client (i) provide a detailed claim chart identifying each accused product or service and mapping every limitation of each asserted claim, (ii) identify any prior art known to your client, including any references cited during prosecution or reexamination, and (iii) substantiate the basis for any damages or licensing demand. We are prepared to discuss the matter further once we have received and reviewed the foregoing.

Sincerely,

[Your Name]

DISCLAIMER. This document is a machine-generated sample. The factual assertions, prior-art citations, and legal arguments above are AI-produced and may contain errors, omissions, or outdated information. Do not transmit this letter, in whole or in part, to any party. This is not legal advice; no attorney-client relationship is created by its existence. Consult a licensed patent attorney before responding to any patent-infringement assertion.

Generated May 14, 2026 by ihatepatenttrolls.com — sample only.